RVL Pharmaceuticals plc
RVLPQ
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -2.25% | -58.81% | 242.90% | 356.38% | -26.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.25% | -58.81% | 242.90% | 356.38% | -26.60% |
| Cost of Revenue | -12.62% | 7.23% | -141.17% | 120.14% | 214.10% |
| Gross Profit | 1.46% | -66.15% | 341.24% | 614.68% | -42.40% |
| SG&A Expenses | -23.99% | -32.04% | -20.79% | -22.00% | -4.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.42% | -28.75% | -23.72% | -16.15% | 5.16% |
| Operating Income | 38.59% | -90.72% | 59.93% | 48.66% | -45.35% |
| Income Before Tax | -102.91% | -67.55% | 5.93% | 44.73% | 45.92% |
| Income Tax Expenses | -140.79% | 177.33% | -185.00% | -80.56% | 194.68% |
| Earnings from Continuing Operations | -97.33% | -70.24% | 6.90% | 45.17% | 44.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -97.33% | -70.24% | 7.11% | 19.11% | 31.71% |
| EBIT | 38.59% | -90.72% | 59.93% | 48.66% | -45.35% |
| EBITDA | 38.88% | -92.16% | 60.20% | 48.72% | -154.02% |
| EPS Basic | -66.02% | -43.08% | 24.27% | 45.12% | 48.73% |
| Normalized Basic EPS | 45.11% | 28.69% | 97.15% | 51.90% | 15.56% |
| EPS Diluted | -66.02% | -43.08% | 24.27% | 45.12% | 48.73% |
| Normalized Diluted EPS | 45.11% | 28.69% | 97.15% | 51.90% | 15.56% |
| Average Basic Shares Outstanding | 18.89% | 18.96% | 22.61% | 47.36% | 33.16% |
| Average Diluted Shares Outstanding | 18.89% | 18.96% | 22.61% | 47.36% | 33.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |